ArticleHuman vaccines & immunotherapeutics2026
Economic and epidemiological burden of HPV-related diseases in the Czech Republic: A claims database analysis.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to examine the economic and epidemiological burden of human papillomavirus (HPV) on both men and women in the Czech Republic. It extended beyond the typically studied cervical cancer to encompass a rising incidence of non-cervical HPV-related cancers. The utilization of administrative healthcare claims data enabled the identification of HPV-related diseases using ICD-10 codes. For each identified disease, the proportion corresponding to disease cases directly attributable to HPV was analyzed in terms of the associated healthcare costs. Furthermore, the years of life lost (YLL) and indirect costs associated with premature mortality were calculated using gender-specific life expectancies and average salaries, employing the human capital approach. The findings indicate that there were over 100,000 incident cases of HPV-related diseases between 2018 and 2020, with the majority of these occurring in females (84.2%), and the average age of the patient was 40.6 y. The total medical costs incurred by HPV-related diseases exceeded 1 billion CZK (€41.1 million) over the study period (2018-2020), with an estimated 27,436 y lost due to premature mortality. The indirect costs, attributable exclusively to productivity losses from premature mortality, amounted to over 3.29 billion CZK (€127.7 million). These results highlight the substantial financial and health burdens HPV imposes on the Czech healthcare system, underscoring the necessity for informed policy-making and cost-effective HPV interventions, including enhanced vaccination and preventive programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.